Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TM4SF4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TM4SF4 Extracellular Domain (EC2)-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View TM4SF4 Products |
| Gene Delivery | TM4SF4 Lentivirus Premade Particles Full-length ORF for stable cell line construction. Ideal for preserving native 4-transmembrane conformation. |
View TM4SF4 Products |
| Benchmark Ab | Anti-TM4SF4 Recombinant Antibody Recombinant positive control derived from benchmark research sequences. |
View TM4SF4 Products |
| Validator | TM4SF4 siRNA Set For target knockdown and specificity validation in vitro. |
View TM4SF4 Products |
| Related Target A | TM4SF1 Subfamily homolog. Critical for off-target counter-screening to ensure therapeutic safety. |
View TM4SF1 Products |
| Related Target B | EGFR Synergistic pathway partner. TM4SF4 overexpression mediates resistance to EGFR TKIs. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of 4-TM Protein | High-titer Lentiviral vectors for stable overexpression in target cell lines, bypassing the instability of detergent-solubilized proteins. |
| Subfamily Cross-Reactivity (e.g., TM4SF1, TM4SF5) | Recombinant EC2 loop proteins for TM4SF family members strictly verified by mass spectrometry to guarantee sequence specificity. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included to calibrate binding and internalization kinetics. |
| False Positives in Knockdown | Sequence-verified, multi-target siRNA pool included for robust gene silencing validation. |
Live TM4SF4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TM4SF4 therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies to antibody-drug conjugates (ADCs) and targeted cell therapies. As first-generation therapies targeting cancer stem cells reach preclinical and early clinical milestones, the next wave of R&D is focusing on overcoming drug resistance in EGFR-mutant non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC). Because TM4SF4 acts as a key driver of radiation and chemotherapy resistance, combining TM4SF4-targeted agents with standard-of-care regimens represents a major frontier in solid tumor oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Biotech Startups, Academic Labs | NSCLC, Hepatocellular Carcinoma | Internalization Assay (Requires sequence-verified EC2-Fc proteins and stable cell lines) |
| Monoclonal Antibody (mAb) | Oncology Research Institutes | Colorectal Cancer, Pancreatic Cancer | ADCC / CDC Assays (Requires high-titer Lentivirus for stable target expression) |
| CAR-T / Cell Therapy | Translational Medicine Centers | Solid Tumors (CSC targeting) | Specificity Screening (Requires subfamily homolog panel including TM4SF1) |